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Objective: We devised a novel strategy, a GnRH antagonist protocol with a GnRH agonist trigger followed by frozen-thawed blastocyst trans-
fers with long zona dissection (LZD). The purpose of this study was to investigate the clinical outcomes of this new strategy according to age.
Methods: Ninety women aged less than 35 (group A) and 32 women aged 35 to 39 (group B) underwent the GnRH antagonist protocol with a 
GnRH agonist trigger in order to obtain many oocytes and prevent early-onset ovarian hyperstimulation syndrome (OHSS). All oocytes were 
cultured to the blastocyst stage and all blastocysts grade 3BB or better were cryopreserved. Embryo transfers were only performed in freeze-
thaw cycles to prevent late-onset OHSS and to overcome embryo-endometrium dyssynchrony. LZD was performed just after thawing to im-
prove hatching and implantation rates.
Results: The average numbers of retrieved oocytes and blastocysts grade 3BB or better were 12.8±5.5 and 4.4±2.6 in group A and 10.9±7.4 
and 2.5±2.2 in group B, respectively, and OHSS did not occur in any of the women. Implantation rates were 46.7% in group A and 39.3% in group 
B. Cumulative clinical pregnancy rates per retrieval were 77.8% in group A and 62.5% in group B. Cumulative ongoing pregnancy rates per re-
trieval were 71.1% in group A and 53.1% in group B.
Conclusion: GnRH antagonist protocol with GnRH agonist trigger followed by frozen-thawed blastocyst transfers with LZD can generate many 
blastocysts without OHSS and maximize cumulative pregnancy rates per retrieval. This strategy is more effective in young women aged less than 
35 than in women aged 35 to 39.
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Introduction
Theoretically, if any IVF strategy simultaneously satisfies the maxi-
mization of the cumulative pregnancy rate per retrieval, the preven-
tion of ovarian hyperstimulation syndrome (OHSS), the prevention of 
multiple pregnancy, and the minimization of inconvenience and cost, 
it may be one of the most ideal methods. The controlled ovarian stim-
ulation (COS) method, which can produce many oocytes without 
OHSS, and the freezing-thawing method, which can assure high sur-
vival, hatching, and implantation rates, will be needed in order to ac-
complish these aims.
In the last decade, the clinical outcomes of frozen-thawed embryo 
transfers were inferior to fresh embryo transfers. However, recently, 
with the developments of vitrification and assisted hatching (AH), 
frozen-thawed embryo transfers showed prominently improved re-
sults [1]. In fact, it has even been reported that the clinical outcomes 
of frozen-thawed embryo transfers are superior to fresh embryo trans-
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fers owing to better embryo-endometrium synchrony [2,3]. It has 
been well known that premature progesterone elevation and em-
bryo-endometrium dyssynchrony in COS cycles impair implantation 
and no pregnancies are achieved when the endometrium is advanc-
ed for more than 3 days [4,5]. If any freezing-thawing method assures 
high survival, hatching, and implantation rates for embryos, frozen-
thawed embryo transfers can routinely substitute for fresh embryo 
transfers. GnRH antagonist protocol with GnRH agonist trigger is not 
commonly used because of severe luteal phase defects and a low 
pregnancy rate, except in patients with high risk of OHSS [6]. Never-
theless, this protocol could be very effective in patients planning for 
frozen-thawed blastocyst transfers, because it can simultaneously 
accomplish the collection of many oocytes and the prevention of 
early-onset OHSS.
Therefore, we devised a novel strategy that combined several meth-
ods as follows: 1) GnRH antagonist protocol with GnRH agonist trig-
ger to obtain many oocytes and to prevent early-onset OHSS, 2) blas-
tocyst culture to screen arrested embryos or low-quality blastocysts 
out, 3) vitrification with artificial shrinkage to improve the survival 
rate of embryos, 4) frozen-thawed embryo transfers to prevent late-
onset OHSS and to synchronize between embryos and the endome-
trium, and 5) assisted hatching (AH) to overcome zona hardening. 
We investigated the clinical outcomes of this new strategy according 
to age in normal responders.
Methods
1.	Patients
A total of 90 women aged less than 35 (group A) and a total of 32 
women aged 35to 39 (group B) were included in this study from July 
2009 to December 2010. The inclusion criteria of patients were de-
fined as follows: 1) basal follicle-stimulating hormone (FSH) level less 
than 10 mIU/mL, 2) normal uterine cavity, and 3) adequate sperm for 
IVF or ICSI. Before controlled ovarian stimulation, all women had their 
endometrial and tubal pathology evaluated by hysteroscopy or hys-
terosalpingography, and if necessary, endometrial or tubal surgery 
were performed.
2.	Controlled	ovarian	stimulation
GnRH antagonist protocol with GnRH agonist trigger was used pre-
ceded by an oral contraceptive preparation for 2 to 3 weeks. 150-450 
IU/day of recombinant FSH (Gonal-F, Merck Serono, Darmstadt, Ger-
many) was administrated from cycle day 2 or 3 and individualized ac-
cording to the antral follicle count, basal FSH, age, and body weight. 
When leading follicles reached the mean diameter of 13 to 14 mm, 
the GnRH antagonist of cetrorelix 0.25 mg/day (Cetrotide, Merck Se-
rono) was administrated. In case folliclular development had been 
slow or insufficient, 75 to 150 IU/day of recombinant LH (Luveris, Mer-
ck Serono) or hMG (Menopur, Ferring, Lausane, Switzerland) were 
added. When the leading follicles reached the mean diameter of 17 
to18 mm, GnRH agonist triptoreline 0.2 mg (Decapeptyl, Ferring) was 
administrated for trigger of ovulation. Oocyte retrieval was performed 
transvaginally under ultrasound guidance 35 to 36 hours after GnRH 
agonist trigger.
3.	Blastocyst	culture	and	selection	
After standard IVF or ICSI, fertilization was assessed 15-18 hours af-
ter insemination by the presence of two pronuclei. All embryos were 
cultured in sequential media G1/G2 in a 6% CO2, 5% O2, and 89% N2 
environment [7].
All blastocysts were evaluated using Gardner and Schoolcraft’s scor-
ing system [8]. In this study, blastocysts more than grade 3BB were 
selected for cryopreservation and embryo transfers.
4.	Vitrification	and	thawing
The vitrification solution (G25E25) was composed of 25% glycerol 
(Sigma) + 25% ethylene glycol (Sigma) + 20% synthetic serum sub-
stitute (SSS) in Dulbecco’s phosphate buffered saline (DPBS) (Gibco, 
Carlsbad, CA, USA). The equilibration solution (G10 and G10E20) was 
composed of 10% glycerol and 10% glycerol + 20% ethylene glycol 
in DPBS with 20% SSS. Artificial shrinkages of all blastocysts grade 
3BB or better were performed with ICSI pipettes, as we described pre-
viously (Figure 1) [9]. After artificial shrinkage, the blastocysts were 
equilibrated in G10 and G10E20 at room temperature for 3 minutes, 
respectively, and exposed in G25E25 for a maximum of 30 seconds. 
An approximate volume of 0.3 μL of vitrification solution containing 
blastocysts (maximum 2) was loaded on the self-manufactured “cap-
ped-pulled straw”, as previously described [9]. After holding on liquid 
nitrogen (LN2) vapor for 10 seconds, the capped-pulled straw was 
plunged into LN2.
Thawing was performed in 1 mL of 0.5, 0.25 mol/L sucrose and 
DPBS with 10% SSS. The tip of the pulled straw was immersed into 1 
mL of 0.5 mol/L sucrose at room temperature. After 3 minutes, the 
blastocysts were transferred into 0.25 mol/L sucrose and DPBS with 
10% SSS at room temperature for 3 minutes each. After washing three 
times in 37°C DPBS with 10% SSS, AH was performed.
5.	Long	zona	dissection	as	AH
AH was performed by long zona dissection (LZD) using ICSI pipettes 
in the process of thawing (Figure 2). Briefly, a frozen-thawed blasto-
cyst was held by holding a pipette in the 9 o’clock direction and then 
the zona pellucida (ZP) was completely penetrated by injection pi-
pette from the 3 o’clock direction to the 9 o’clock direction. Thereaf-
ter, a large split was created by LZD using holding and injection pi-www.eCERM.org
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pettes.
6.	Endometrial	preparation	and	blastocyst	transfer
Oral contraceptives was administrated from the preceding men-
strual cycle day 2 to 4 and leuprolide acetate 0.5 mg/day (Lucrin, Ab-
bott, IL, USA) was administrated from the preceding menstrual cycle 
day 21 with a 5-day overlap of the GnRH agonist and oral contracep-
tives. The suppressed serum progesterone and the early proliferative 
endometrial pattern on transvaginal ultrasound were confirmed be-
fore sequentially increasing the doses of oral estradiol valerate (Prog-
ynova, Bayer Schering, Leverkusen, Germany). In general, oral estra-
diol valerate (2 mg) was administrated once a day on cycle days 2 to 
5, twice a day on cycle days 6 to 9, and three times a day on cycle 
days 10 to14. In case endometrial thickness on transvaginal ultra-
sound was less than 7 mm by cycle day 14, oral estradiol valerate (2 
mg) four times a day was administered. For luteal support, oral estra-
diol valerate (2 mg) twice a day and vaginal progesterone (Crinone 
gel 8%, Merck Serono) once a day were administrated from cycle day 
15. Frozen-thawed blastocysts were transferred on cycle day 20 or 5 
days after the start of luteal support. The number of transferred blas-
tocysts, ranging from one to three, was decided by the patient.
7.	Outcome	measures	and	statistical	analyses
Implantation and clinical pregnancy were defined as the presence 
of a gestational sac with cardiac activity at 6 weeks of pregnancy. On-
going pregnancy was defined as the presence of a gestational sac 
with cardiac activity at 12 weeks of pregnancy. OHSS was identified 
by the presence of ascites on day 3 after oocyte retrieval. The clinical 
outcomes of frozen-thawed blastocyst transfers were analyzed by 
the Student’s t test, chi-squared test, or Fisher’s exact test. A value of 
p less than 0.05 was considered to be statistically significant. Data are 
expressed as mean±SD unless otherwise specified.
Figure	1. Artificial shrinkage using ICSI pipettes. (A) Locate inner cell mass in the 6 or 12 o’clock direction and hold a blastocyst. (B) Insert injec-
tion pipette from the 3 o’clock direction. (C) Aspirate blastocoel fluid. (D) Blastocyst after artificial shrinkage.
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Results
Table 1 shows the patient characteristics of group A (women aged 
less than 35) and group B (women aged 35-39).
Table 2 shows the clinical outcomes for the GnRH antagonist proto-
col with a GnRH agonist trigger. The average numbers of retrieved 
oocytes and 2 PN embryos were 12.8±5.5 and 10.1±4.9 in group A 
and 10.9±7.4 and 8.3±5.4 in group B, respectively. The average num-
bers and average formation rates of blastocysts grade 3BB or better 
were 4.4±2.6 and 42.6±16.4% in group A and 2.5±2.2 and 25.3± 
18.0% in group B, respectively. OHSS did not exist in any of the pa-
tients on day 3 after oocyte retrieval. Group A showed higher trends 
than group B in terms of all variables, except incidence of OHSS. In 
particular, the average numbers and average formation rates of blas-
tocysts grade 3BB or better were significantly higher in group A than 
group B (p less than 0.05). Table 3 shows the distribution of patients 
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Figure	2. Long zona dissection using ICSI pipettes just after thawing. (A) Hold a blastocyst in the 9 o’clock direction. (B) Insert the injection pi-
pette from the 3 o’clock direction. (C) Penetrate through the perivitelline space to the 9 o’clock direction. (D) Rub and flick the zona pellucida (ZP) 
using holding and injection pipettes. (E) Dissected ZP (arrows). (F) Hatching blastocyst. (G) Hatched blastocyst. (H) Remnant ZP after hatching.
Table	1. Patients’ characteristics
Characteristics Group A (n=90) Group B (n=32)
Age (yr) 31.1±2.8 37.0±1.5
Body mass index (kg/m
2) 22.1±2.7 22.4±2.5
Duration of infertility (yr) 3.2±1.5 4.5±2.8
Prior IVF cycles (n) 1.1±0.8 2.0±1.5
Basal serum FSH (mIU/mL) 4.9±1.9 6.4±2.6
Starting dose of FSH (IU) 218.3±21.6 267.2±38.4
Total dose of FSH (IU) 2,035.0±249.1 2,578.1±460.6
Causes of infertility
Male factor 31/90 (34.4) 11/32 (34.4)
Tubal factor 18/90 (20.0) 6/32 (18.8)
Endometriosis 10/90 (11.1) 3/32 (9.4)
Ovulatory factor 14/90 (15.6) 2/32 (6.2)
Unexplained/other 4/90 (4.4) 4/32 (12.5)
Combined factor 13/90 (14.4) 6/32 (18.8)
Values are presented as mean±SD or number (%).
Table	2. Clinical outcomes for GnRH antagonist protocol with GnRH 
agonist trigger
Variables  Group A 
(n=90)
Group B 
(n=32) p-value
No. of oocyte retrieval cycles 90 32
Average No. of retrieved oocytes 12.8±5.5 10.9±7.4 0.130
Average No. of 2PN embryos 10.1±4.9 8.3±5.4 0.076
Average No. of blastocysts≥grade 3BB 4.4±2.6 2.5±2.2 <0.001
Blastocyst formation rates
a (%) 42.6±16.4 25.3±18.0 <0.001
Incidence of OHSS (%) 0 0 NS
OHSS, ovarian hyperstimulation syndrome; NS, not statistically significant.
aFormation rates from 2PN embryos to blastocysts≥grade 3BB.
Table	3. Distribution of patients according to number of blastocysts 
≥grade 3BB
Number of blastocysts≥grade 3BB Group A (n=90) Group B (n=32)
0 4 (4.4) 6 (18.8)
1 10 (11.1) 8 (25.0)
2 9 (10.0) 2 (6.3)
3 9 (10.0) 4 (12.5)
4 18 (20.0) 9 (28.1)
≥5 40 (44.4) 3 (9.4)
Values are presented as number (%).www.eCERM.org
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according to the number of blastocysts grade 3BB or better. In group 
A, 4.4% (4/90) of the patients had no blastocysts as did 18.8% (6/32) 
in group B. In group A, 11.1% (10/90) of the patients had 1 blastocyst 
and in group B 25.0% (8/32) did. In group A, 64.4% (58/90) of the pa-
tients had more than 4 blastocysts as did 37.5% (12/32) in group B. 
Table 4 shows the clinical outcomes for frozen-thawed blastocyst 
transfers. The average recovery and survival rates of frozen-thawed 
blastocysts were 100% and 95.9% in group A and 100% and 94.9% 
in group B, respectively. The average numbers of transferred blasto-
cysts of grade 3BB or better were 2.1±0.6 in group A and 1.6±0.6 in 
group B. Implantation rates were 46.7% in group A and 39.3% in group 
B. Clinical pregnancy and ongoing pregnancy rates per transfer were 
72.5% and 62.7% in group A and 58.8% and 50.0% in group B, re-
spectively. Cumulative clinical pregnancy and cumulative ongoing 
pregnancy rates per retrieval were 77.8% and 71.1% in group A and 
62.5% and 53.1% in group B, respectively. Group A showed the high-
er rates than group B for all variables, except recovery and survival 
rates, as well as average numbers of transferred blastocysts of grade 
3BB or better.
Discussion
Our strategy combined several methods as follows: 1) A GnRH an-
tagonist protocol with a GnRH agonist trigger, 2) blastocyst culture 
and selection, 3) frozen-thawed blastocyst transfers, 4) vitrification 
with artificial shrinkage, and 5) LZD as AH.
Firstly, the GnRH antagonist protocol with GnRH agonist trigger 
was used for the prevention of early-onset OHSS and the acquisition 
of many oocytes. A GnRH agonist trigger is not generally used be-
cause of severe luteal phase defects and low pregnancy rates, but 
this disadvantage can be transformed into an advantage in patients 
planning for frozen-thawed blastocyst transfers [6]. This protocol is 
very useful in high responders, especially in patients with polycystic 
ovary syndrome. Even though early-onset OHSS occurs temporarily 
in patients with severe polycystic ovary syndrome, it disappears rap-
idly after oocyte retrieval owing to the short effect of GnRH agonist. 
In addition, this protocol is superior to IVM with regard to the num-
bers of mature oocytes and blastocysts. In this study, we use GnRH 
agonist for ovulation triggering, but in other cases like low respond-
ing or old age groups, we recommend hCG for ovulation triggering.
These advantages confirmed in the results of our study that the av-
erage numbers of retrieved oocytes and blastocysts that were grade 
3BB or better were 12.8±5.5 and 4.4±2.6 in women aged less than 
35 (group A) and 10.9±7.4 and 2.5±2.2 in women aged 35-39 (group 
B), respectively, and that OHSS did not exist in any of the patients on 
day 3 after oocyte retrieval. Theoretically, when the implantation rate 
is 46.7%, the patients with more than four blastocysts can achieve a 
cumulative clinical pregnancy rate per retrieval of approximately 92%. 
In reality, 64.4% (58/90) of the patients of group A showed cumula-
tive clinical pregnancy rate of approximately 96% per retrieval. There-
fore, the COS method, which can procure many oocytes without OHSS, 
is very important in order to maximize the cumulative clinical preg-
nancy rate per retrieval.
The potential advantages of blastocyst culture are to screen aneu-
ploidic or arrested embryos out, to synchronize the embryonic stage 
with the uterine environment, and to reduce the chance of embryon-
ic expulsion from the uterus [7,10,11]. Also, cryopreservation is more 
successful at the blastocyst stage than earlier stages [12]. Above all, 
in our experience, good-quality embryos in the cleavage stage do not 
grow into blastocysts of grade 3BB or better and are frequently arrest-
ed in the cleavage and morula stage.
Gardner et al. [13,14] have reported the clinical outcomes of fresh 
blastocyst transfer cycles according to blastocyst score. Implantation 
and clinical pregnancy rates were 69.9% and 86.8% in the group of 2 
blastocysts grade 3AA or better transferred and were 56.0% and 76.0% 
in the group of two blastocysts grade 3BB or better transferred, re-
Table	4. Clinical outcomes for frozen-thawed blastocyst transfers
Variables Group A (n=90)
a Group B (n=32)
b p-values
No. of frozen-thawed cycles 102 34
No. of frozen-thawed blastocysts 210 59
Recovery rates after thawing 100% (219/219) 100% (59/59) NS
Survival rates after thawing 95.9% (210/219) 94.9% (56/59) NS
Average No. of transferred blastocysts  2.1±0.6 1.6±0.6 0.001
Implantation rate 46.7% (98/210) 39.3% (22/56) 0.324
Clinical pregnancy rates per transfer  72.5% (74/102) 58.8% (20/34) 0.134
Ongoing pregnancy rates per transfer 62.7% (64/102) 50.0% (17/34) 0.108
Cumulative clinical pregnancy rates per retrieval 77.8% (70/90)
a 62.5% (20/32)
b 0.092
Cumulative ongoing pregnancy rates per retrieval 71.1% (64/90)
a 53.1% (17/32)
b 0.064
NS, not statistically significant.
aFour women were not transferred owing to no blastocysts≥grade 3BB; 
bSix women were not transferred owing to no blastocysts≥grade 3BB.  http://dx.doi.org/10.5653/cerm.2012.39.1.33
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spectively. Recently, Goto et al. [1] have reported the clinical outcomes 
of 1,488 single frozen-thawed blastocyst transfers according to blas-
tocyst score and age. The implantation rates were 50.5% to 70.1% in 
the groups of one blastocyst grade 4BB or better transferred and were 
45.6% to 51.7% in the groups of one blastocyst of grade 3AA, 3AB, or 
3BA transferred, respectively. These reports showed that implantation 
rates differ according to the blastocyst score and age. In our study, 
the selected blastocysts were at least grade 3BB and implantation 
rates were 46.7% in women aged less than 35% and 39.3% in wom-
en aged 35 to 39. Goto et al. [1] and our studies showed that frozen-
thawed blastocysts can provide high enough implantation rates.
Frozen-thawed blastocyst transfers were used for the prevention of 
delayed-onset OHSS and better embryo-endometrium synchrony. It 
has been well known that no pregnancies are achieved in cases of 
endometrial advancement exceeding 3 days in COS cycles [5]. The 
cryopreservation of all blastocysts has several advantages owing to a 
lack of demand for embryo-endometrium synchrony in the COS cy-
cle. All of the good-quality blastocysts that develop on day 5 or day 6 
can be always transferred under complete embryo-endometrium 
synchrony. In COS cycles, the implantation rate for day 6 blastocysts 
is lower than that of day 5 blastocysts; however, in frozen-thawed cy-
cles, the clinical outcomes of day 6 blastocysts are similar to day 5 blas-
tocysts [15]. Also, in donor-recipient cycles, the complex processes 
for embryo-endometrium synchrony are not required. With the com-
plete separation between oocyte retrieval and embryo transfer, COS 
and monitoring are very simple and free from the control of the go-
nadotropin dose as well as the timing of GnRH antagonist and ovula-
tion trigger. Transvaginal ultrasound alone is enough to monitor COS 
cycles.
Earlier, we reported vitrification with artificial shrinkage using ICSI 
pipettes, which showed a high survival rate of more than 90% in mouse 
expanding blastocysts [9]. Our study showed that the recovery rate 
was 100% and survival rate was approximately 95%. The recovery 
and survival rates prominently affect the cumulative pregnancy rates 
per retrieval, especially in patients with small numbers of blastocysts; 
therefore, the high recovery and survival rates are required for the 
strategy of frozen-thawed blastocyst transfers in all patients.
LZD using an ICSI pipette as mechanical AH was used to overcome 
zona hardening. LZD is very important for achieving a high implanta-
tion of blastocysts. LZD or controlled zona dissection was first report-
ed in mouse and human fresh embryos by Lyu et al. [16]. In 8-cell mou-
se embyos, LZD with a large slit (beyond two-thirds of the zona di-
ameter) significantly enhanced complete hatching rates compared 
to three-dimensional partial zona dissection and no AH: 93.9% vs. 
62.0% vs. 38.8%, respectively. In human blastocysts, LZD with a large 
slit significantly enhanced complete hatching rates compared to a 
moderate slit (two-fifths of ZP diameter): 100% vs. 71.8%, respectively. 
They demonstrated that the complete hatching rate of the AH group 
is higher than the no AH group and a hole size created on ZP is im-
portant for complete hatching because the zona opening of small or 
moderate size can often trap the ICM. Also, we havepreviously report-
ed the effects of LZD using ICSI pipettes in frozen-thawed mouse blas-
tocysts (Jo et al. [9]). Complete hatching rates were significantly high-
er in the AH group than the no AH group: 100% vs. 50%, respectively. 
These reports showed that the complete hatching rates of the no AH 
group is very low in frozen-thawed cycles as well as fresh cycles and 
LZD can completely overcome zona hardening.
In our study, LZD were performed just after thawing in order to pre-
vent potential contamination or infection during in vitro culture and 
cryopreservation. Compared with other methods, this method has a 
small variation regarding clinical outcomes and a large slit could be 
easily created by an embryologist handling a micromanipulator ow-
ing to the wide perivitelline space around the shrunken blastocyst.
This novel strategy can resolve many problems that are currently 
faced in IVF programs, and can simplify the complex processes relat-
ed to COS and monitoring. In addition, this strategy can simultane-
ously satisfy the ideal aims of IVF program such as the maximization 
of the cumulative pregnancy rate per retrieval, the prevention of 
OHSS in high responders such as patients who had polycystic ovarian 
syndrome and multiple pregnancy, and the minimization of patients’ 
inconvenience and cost. In particular, this strategy is more useful in 
young women aged less than 35 than it is in older women aged 35 
to 39. 
This study was limited by a small sample size and retrospective de-
sign. However, it shows the need for further case-controlled prospec-
tive studies. 
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